Animal sources, restructuring techniques, long-lasting filling of three main technological routes, and the adhesive protein track has entered the age of hot competition。
On 10 december 2025, the national drug authority (nmpa) approved, in one instance, two medical units for type iii glue proteins, representing 14 of the total number of domestically certified “iii type glue proteins”。
This means not only a great deal of market choice, but also a new phase in the parallel development of the three technological routes of gelatin protein filling from mono-product competition to animal extraction, humanization techniques and long-lasting composite filling。
Cartography in the united states
Animal source glue:
Eight of the highest percentages. New and old players
As the most technically mature route, the animal source glue is currently in possession of eight products and is the dominant force in the market. The entry of new players is an attempt to create differential advantages from concentrations, materials, application levels, etc。
A fresh entry, high-strikes: the most recently approved abigail and zongshan organisms are remarkable. The product of zhongshan, which is labelled as the highest in the current market at 45 mg/ml concentrations and is clearly labelled for “under-skin injection”, has broken through the depths of injection in the traditional true skin and attempted to widen the boundaries of adaptive disorders。
Traditional giants, with deep roots: as early market educators, bi-aesthetics have accumulated nearly 2 million clinical uses in the asia-pacific region, covering a variety of adaptive disorders such as nasal lasagna, eyebrow stripes, fish tails, and mature product matrices。
A breakdown of the tracks, precise caloric position: the faucet masters of the faucets have sustained it for 10 to 16 months with long effects, while the corecon organisms have introduced the country's first “open-box-in” animal adhesive protein solution, which addresses the pain point of the traditional product requiring pre-operative resolvation and has led to operational improvements。
It is not surprising that the market for animal gelatines has shifted from a “no-no-no” problem to “no-no-no” competition. If a new player is to receive a piece, he or she must produce hard core indicators on composition purity, concentration, application or ease of use, otherwise it will be difficult to shake the market position of the pioneers。
Long-acting glue:
The two males are still strong
The long-acting glue product, represented by elbeth and belifle, is essentially a composite filling agent for the “gela protein + pmma microball”。
In terms of effect, the adhesion function is instant filling, while the pmma microballs are sustained by stimulating self-emergence (usually up to five years). These two imported products are located at a high level, satisfying the extreme quest of some users for sustainability。
However, the market threshold for long-lasting filling is high and user decisions are prudent. While market patterns remain strong, their presence reflects the dual demand for “immediate effects + long-term regeneration” and provides an important reference for future technological developments。
Reorganium protein:
Technology drives the future. Two giants are on board
The recombinant glue protein represents the technological frontier and is currently dominated by two leading firms, the bourgeois and giants. In addition to obtaining a total of four registration certificates for category iii, they have completed the layout of the freezed dry fibres, solubles, gels and totals, demonstrating full r & d and industrialization capabilities。
Carbobiology: product matrix is complete, leading the market. Under its banner, it has violin (frozen dry fibres), a platinum platinum platinum platinum needle (slubber) in cooperation with shureco, and the most recently approved three products of hivecol (condensation)。
Of these, vitamin sales have exceeded 2 million, with high market recognition. New gel product positioning mid-face capacity fills with support and filling functions to expand the application scene of the recombinant platitude from wrinkle to plastic。
Giant organisms: accurate in, steady in. Its approval in october for the “reorganization of the alpha-1 sub-gel protein dry fibres” focused on the correction of corrosive wrinkles, marked its formal integration into the armaments iii bureau。
Of course, in addition to the 14 above-mentioned certificates, dozens of enterprises, including wah hee-bian and marome, are reconfiguring the glue protein line. According to the approval cycle, the period 2026 to 2027 will be the period during which more players will be authorized for “armament iii”。
This means that, starting next year, more glued protein injection products will be available on the market, with the market at risk。
